KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Account Payables (2016 - 2026)

Biocryst Pharmaceuticals filings provide 12 years of Change in Account Payables readings, the most recent being $35.4 million for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 73.33% to $35.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.8 million, a 291.19% increase, with the full-year FY2025 number at $57.8 million, up 291.19% from a year prior.
  • Change in Account Payables hit $35.4 million in Q4 2025 for Biocryst Pharmaceuticals, up from $24.6 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $49.2 million in Q4 2023 to a low of -$47.1 million in Q1 2025.
  • Median Change in Account Payables over the past 5 years was $12.0 million (2021), compared with a mean of $5.1 million.
  • Biggest five-year swings in Change in Account Payables: tumbled 237.47% in 2022 and later skyrocketed 11022.87% in 2024.
  • Biocryst Pharmaceuticals' Change in Account Payables stood at $22.7 million in 2021, then crashed by 76.76% to $5.3 million in 2022, then soared by 832.17% to $49.2 million in 2023, then crashed by 58.54% to $20.4 million in 2024, then soared by 73.33% to $35.4 million in 2025.
  • The last three reported values for Change in Account Payables were $35.4 million (Q4 2025), $24.6 million (Q3 2025), and $45.0 million (Q2 2025) per Business Quant data.